Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Singapore National Eye Centre |
---|---|
Information provided by: | Singapore National Eye Centre |
ClinicalTrials.gov Identifier: | NCT00344617 |
To assess the use of Avastin for the management of serosanguinous maculopathy
Condition | Intervention | Phase |
---|---|---|
Choroidal Neovascularisation Polypoidal Choroidal Vasculopathy |
Drug: Bevacizumab (tradename: Avastin) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Off-Label Use of AVASTIN (BEVACIZUMAB)Intravitreal Injection For the Treatment of Serosanguinous Maculopathy |
Estimated Enrollment: | 50 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | May 2008 |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | R452/01/2006 |
Study First Received: | June 23, 2006 |
Last Updated: | September 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00344617 History of Changes |
Health Authority: | Singapore: Domain Specific Review Boards; Singapore: Health Sciences Authority |
Choroidal neovascularisation Polypoidal choroidal vasculopathy Intravitreal injection Avastin |
Uveal Diseases Eye Diseases Metaplasia Choroid Diseases |
Bevacizumab Neovascularization, Pathologic Angiogenesis Inhibitors Choroidal Neovascularization |
Uveal Diseases Antineoplastic Agents Eye Diseases Growth Substances Choroid Diseases Physiological Effects of Drugs Bevacizumab Angiogenesis Inhibitors |
Pharmacologic Actions Choroidal Neovascularization Pathologic Processes Therapeutic Uses Metaplasia Growth Inhibitors Neovascularization, Pathologic Angiogenesis Modulating Agents |